| 54.74 0.16 (0.29%) | 04-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 70.9 | 1-year : | 77.08 |
| Resists | First : | 60.7 | Second : | 66 |
| Pivot price | 59.47  |
|||
| Supports | First : | 52.13 | Second : | 43.38 |
| MAs | MA(5) : | 54.95 |
MA(20) : | 60.26 |
| MA(100) : | 64.78  |
MA(250) : | 59.44 |
|
| MACD | MACD : | -2.7 |
Signal : | -2.1 |
| %K %D | K(14,3) : | 12.5 |
D(3) : | 7.4 |
| RSI | RSI(14): 32.9 |
|||
| 52-week | High : | 76.98 | Low : | 42.2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IMCR ] has closed above bottom band by 18.5%. Bollinger Bands are 38.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 55.18 - 55.45 | 55.45 - 55.69 |
| Low: | 52.08 - 52.38 | 52.38 - 52.66 |
| Close: | 54.23 - 54.74 | 54.74 - 55.2 |
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Tue, 16 Apr 2024
Immunocore Holdings plc (NASDAQ:IMCR) Sees Significant Increase in Short Interest - MarketBeat
Tue, 16 Apr 2024
Immunocore Holdings plc (NASDAQ:IMCR) Sees Large Growth in Short Interest - Defense World
Mon, 15 Apr 2024
Immunocore Holdings Becomes Oversold (IMCR) - Nasdaq
Fri, 05 Apr 2024
Immunocore Holdings plc (NASDAQ:IMCR) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Fri, 05 Apr 2024
Immunocore Holdings plc (NASDAQ:IMCR) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Fri, 05 Apr 2024
Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%? - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 50 (M) |
| Shares Float | 32 (M) |
| Held by Insiders | 4.4 (%) |
| Held by Institutions | 82.2 (%) |
| Shares Short | 4,610 (K) |
| Shares Short P.Month | 4,230 (K) |
| EPS | -1.42 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.42 |
| Profit Margin | -22.2 % |
| Operating Margin | -26.3 % |
| Return on Assets (ttm) | -6.8 % |
| Return on Equity (ttm) | -15.7 % |
| Qtrly Rev. Growth | 12.1 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 5 |
| EBITDA (p.s.) | -1.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 3 (M) |
| Levered Free Cash Flow | 14 (M) |
| PE Ratio | -38.55 |
| PEG Ratio | 0 |
| Price to Book value | 7.37 |
| Price to Sales | 10.93 |
| Price to Cash Flow | 927.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|